We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+8.11%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.6B
AUM Growth
+$562M
(+28%)
Cap. Flow
+$523M
Cap. Flow
% of AUM
20.1%
Top 10 Holdings %
Top 10 Hldgs %
52.45%
Holding
38
New
6
Increased
14
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$62.7M |
| 2 |
Viatris
VTRS
|
+$49M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$45.5M |
| 4 |
Perrigo
PRGO
|
+$40.5M |
| 5 |
Nektar Therapeutics
NKTR
|
+$38.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$67.5M |
| 3 |
Tenet Healthcare
THC
|
+$62.2M |
| 4 |
GSK
GSK
|
+$58.6M |
| 5 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$49.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
| $45.5M | 1.75% |
1,000,000
+175,000
| +21% | +$8.51M |
|
|
KTWO
27
DELISTED
K2M Group Holdings, Inc
KTWO
| $45M | 1.73% |
2,000,000
+650,677
| +48% | +$13.7M |
|
|
MNK
28
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $35.5M | 1.36% |
+1,900,000
| New | +$30.2M |
|
|
WMGI
29
DELISTED
Wright Medical Group Inc
WMGI
| $32.5M | 1.25% |
1,250,000
+435,000
| +53% | +$9.94M |
|
|
ENDP
30
DELISTED
Endo International plc
ENDP
| $23.6M | 0.91% |
2,500,000
| – | – |
|
|
EGRX
31
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $19.8M | 0.76% |
+261,100
| New | +$16.4M |
|
32
Zymeworks
ZYME
$1.67B
| $18.5M | 0.71% |
+1,250,000
| New | +$19.4M |
|
33
Surgery Partners
SGRY
$2.08B
| $2.01M | 0.08% |
135,084
| – | – |
|
34
Bausch Health
BHC
$2.25B
| – | – |
-1,500,000
| Closed | -$23.9M |
|
|
35
Bristol-Myers Squibb
BMY
$132B
| – | – |
-1,250,000
| Closed | -$67.5M |
|
|
36
GSK
GSK
$104B
| – | – |
-1,200,000
| Closed | -$58.6M |
|
37
Prothena Corp
PRTA
$440M
| – | – |
-250,000
| Closed | -$9.18M |
|
|
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-1,000,000
| Closed | -$9.56M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Camber Capital Management held 38 positions worth $2.6B, up 28% from $2.04B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Camber Capital Management deployed $523M of net new capital in Q2 2018, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 1,900,000 shares worth $35.5M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 87% a quarter earlier.
On the sell side, the largest reduction was Shire pic, an estimated $72.6M trimmed.
- Camber Capital Management's largest Q2 2018 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 1,900,000 shares worth $35.5M.
- Camber Capital Management added most to Momenta Pharmaceuticals, Inc. in Q2 2018, an estimated $62.7M increase.
- Camber Capital Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $72.6M.
- Camber Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $67.5M.
- Camber Capital Management's ten largest holdings make up 52% of its $2.6B portfolio in Q2 2018.
- Camber Capital Management opened 6 new positions and closed 5 in Q2 2018.
- Camber Capital Management's portfolio value rose 28% quarter-over-quarter to $2.6B.
Based on Camber Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.